Thrivent Financial for Lutherans
TGTX icon

Thrivent Financial for Lutherans’s TG Therapeutics TGTX Stock Holding History

Thrivent Financial for Lutherans’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.75M Sell
86,550
-4,202
-5% -$172K 0.01% 1024
2026
Q1 		$3.02M Sell
90,752
-2,673
-3% -$79.7K 0.01% 1170
2025
Q4 		$2.79M Sell
93,425
-4,461
-5% -$146K ﹤0.01% 1252
2025
Q3 		$3.54M Sell
97,886
-1,829
-2% -$60.2K 0.01% 1002
2025
Q2 		$3.59M Buy
99,715
+1,677
+2% +$62.4K 0.01% 980
2025
Q1 		$3.87M Sell
98,038
-5,130
-5% -$173K 0.01% 932
2024
Q4 		$3.1M Sell
103,168
-1,596
-2% -$45.8K 0.01% 1152
2024
Q3 		$2.45M Buy
+104,764
New +$2.29M ﹤0.01% 1301
2024
Q2 		– Sell
-38,490
Closed -$586K – 2589
2024
Q1 		$586K Sell
38,490
-17,730
-32% -$282K ﹤0.01% 2170
2023
Q4 		$960K Sell
56,220
-10,963
-16% -$127K ﹤0.01% 1863
2023
Q3 		$562K Buy
+67,183
New +$937K ﹤0.01% 2079

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Thrivent Financial for Lutherans's TGTX Position: Q2 2026 in Review

Thrivent Financial for Lutherans reduced its TG Therapeutics (TGTX) stake by 4.6% in Q2 2026, selling an estimated $172K and leaving 86,550 shares worth $4.75M. The position accounts for 0.01% of the portfolio, ranked #1024.

Thrivent Financial for Lutherans first reported a position in TGTX in Q3 2023 and has held it in 11 quarters since. 427 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Thrivent Financial for Lutherans held 86,550 shares of TG Therapeutics worth $4.75M as of Q2 2026.
  • Thrivent Financial for Lutherans sold 4,202 TG Therapeutics shares in Q2 2026, an estimated $172K.
  • TG Therapeutics made up 0.01% of Thrivent Financial for Lutherans's portfolio in Q2 2026, its #1024 holding.
  • Thrivent Financial for Lutherans first reported a position in TG Therapeutics in Q3 2023 and has held it in 11 quarters since.
  • 427 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Thrivent Financial for Lutherans's 13F filing for Q2 2026, filed 14 Aug 2026.